These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34305015)

  • 1. Serum bile acids in cystic fibrosis patients - glycodeoxycholic acid as a potential marker of liver disease.
    Drzymała-Czyż S; Dziedzic K; Szwengiel A; Krzyżanowska-Jankowska P; Nowak JK; Nowicka A; Aringazina R; Drzymała S; Kashirskaya N; Walkowiak J
    Dig Liver Dis; 2022 Jan; 54(1):111-117. PubMed ID: 34305015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis.
    Bettinardi N; Felicetta I; Tomasi PA; Colombo C
    Clin Chem Lab Med; 2003 Mar; 41(3):311-6. PubMed ID: 12705340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycodeoxycholic acid levels as prognostic biomarker in acetaminophen-induced acute liver failure patients.
    Woolbright BL; McGill MR; Staggs VS; Winefield RD; Gholami P; Olyaee M; Sharpe MR; Curry SC; Lee WM; Jaeschke H;
    Toxicol Sci; 2014 Dec; 142(2):436-44. PubMed ID: 25239633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile acids cycle disruption in patients with nasopharyngeal carcinoma promotes the elevation of interleukin-10 secretion.
    Wang CS; Liu SH; Peng J; Tang C; Zhu WG
    Afr Health Sci; 2015 Dec; 15(4):1200-3. PubMed ID: 26958021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fasting serum bile acid levels in relation to liver histopathology in cystic fibrosis.
    Strandvik B; Samuelson K
    Scand J Gastroenterol; 1985 Apr; 20(3):381-4. PubMed ID: 4001847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress markers, secondary bile acids and sulfated bile acids classify the clinical liver injury type: Promising diagnostic biomarkers for cholestasis.
    Masubuchi N; Sugihara M; Sugita T; Amano K; Nakano M; Matsuura T
    Chem Biol Interact; 2016 Aug; 255():83-91. PubMed ID: 26325587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with
    Tabori H; Schneider J; Lüth S; Zagoya C; Barucha A; Lehmann T; Kauf E; Barth A; Mainz JG
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary bile acid excretion in correlation to liver histopathology in cystic fibrosis.
    Arborgh B; Eklund A; Norman A; Strandvik B
    Scand J Gastroenterol; 1980; 15(1):73-80. PubMed ID: 7367826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum glycine-conjugated bile acids in pediatric hepatobiliary disorders.
    Lloyd-Still JD; Demers LM
    Am J Clin Pathol; 1979 Apr; 71(4):444-51. PubMed ID: 443203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
    Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
    Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on: "Serum bile acids in cystic fibrosis patients - glycodeoxycholic acid as a potential marker of liver disease".
    Choday S
    Dig Liver Dis; 2022 Nov; 54(11):1592-1593. PubMed ID: 36028439
    [No Abstract]   [Full Text] [Related]  

  • 13. Author's reply: "Serum bile acids in cystic fibrosis patients-Glycodeoxycholic acid as a potential marker of liver disease".
    Drzymała-Czyż S; Nowak JK; Walkowiak J
    Dig Liver Dis; 2022 Nov; 54(11):1594. PubMed ID: 36151015
    [No Abstract]   [Full Text] [Related]  

  • 14. Serum bile acid composition in patients with cystic fibrosis.
    Setchell KD; Smethurst P; Giunta AM; Colombo C
    Clin Chim Acta; 1985 Sep; 151(2):101-10. PubMed ID: 4042374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
    Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
    J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Phospholipid Fatty Acid Composition in Cystic Fibrosis Patients with and without Liver Cirrhosis.
    Drzymała-Czyż S; Szczepanik M; Krzyżanowska P; Duś-Żuchowska M; Pogorzelski A; Sapiejka E; Juszczak P; Lisowska A; Koletzko B; Walkowiak J
    Ann Nutr Metab; 2017; 71(1-2):91-98. PubMed ID: 28738321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Bile Acids Are Associated with Pathological Progression of Hepatitis B-Induced Cirrhosis.
    Wang X; Xie G; Zhao A; Zheng X; Huang F; Wang Y; Yao C; Jia W; Liu P
    J Proteome Res; 2016 Apr; 15(4):1126-34. PubMed ID: 25964117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
    Lindblad A; Glaumann H; Strandvik B
    Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor.
    Ellis E; Axelson M; Abrahamsson A; Eggertsen G; Thörne A; Nowak G; Ericzon BG; Björkhem I; Einarsson C
    Hepatology; 2003 Oct; 38(4):930-8. PubMed ID: 14512880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile acid malabsorption in cystic fibrosis with and without pancreatic insufficiency.
    Colombo C; Roda A; Roda E; Piceni Sereni L; Brega A; Fugazza R; Giunta A
    J Pediatr Gastroenterol Nutr; 1984 Sep; 3(4):556-62. PubMed ID: 6481566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.